U.S. markets open in 5 hours 55 minutes
  • S&P Futures

    4,571.50
    +6.25 (+0.14%)
     
  • Dow Futures

    35,687.00
    +43.00 (+0.12%)
     
  • Nasdaq Futures

    15,576.00
    +31.00 (+0.20%)
     
  • Russell 2000 Futures

    2,288.70
    -5.20 (-0.23%)
     
  • Crude Oil

    83.56
    -1.09 (-1.29%)
     
  • Gold

    1,787.50
    -5.90 (-0.33%)
     
  • Silver

    24.05
    -0.04 (-0.16%)
     
  • EUR/USD

    1.1610
    +0.0008 (+0.07%)
     
  • 10-Yr Bond

    1.6190
    0.0000 (0.00%)
     
  • Vix

    15.77
    +0.53 (+3.48%)
     
  • GBP/USD

    1.3753
    -0.0010 (-0.07%)
     
  • USD/JPY

    113.9130
    -0.2160 (-0.19%)
     
  • BTC-USD

    60,339.12
    -2,064.02 (-3.31%)
     
  • CMC Crypto 200

    1,467.04
    -38.11 (-2.53%)
     
  • FTSE 100

    7,276.53
    -1.09 (-0.01%)
     
  • Nikkei 225

    29,098.24
    -7.77 (-0.03%)
     

Cassava Sciences' Simufilam Data Shows Improved Cognition In Alzheimer's Disease

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Cassava Sciences Inc (NASDAQ: SAVA) has announced top-line data from a pre-planned interim analysis of an ongoing open-label study of simufilam in mild-to-moderate Alzheimer's disease.

  • Related Content: Cassava CEO Goes Offensive Over Simufilam Data Allegations.

  • The National Institutes of Health-funded study showed ADAS-Cog11 scores improved an average of 3.2 points from baseline in the first 50 study subjects who completed 12 months of treatment.

  • 68% of study subjects improved on ADAS-Cog at 12 months; these study subjects improved an average of 6.8 points.

  • An additional 20% of study subjects declined less than 5 points on ADAS-Cog at 12 months; these study subjects declined an average of 2.5 points.

  • An independent, published meta-analysis of patients with mild-to-moderate Alzheimer's disease reports an average decline of 5.5 points over 12 months.

  • The drug was well-tolerated. There are no drug-related serious adverse events through the 12-month interim analysis.

  • Simufilam is a small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain.

  • Altered FLNA in the brain disrupts the normal function of neurons, leading to Alzheimer's pathology, neurodegeneration, and neuroinflammation.

  • Price Action: SAVA stock is up 3.48% at $51.02 during the market session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.